BARICITINIB (baricitinib) by Aurobindo Pharma is (jak) inhibitor. Approved for more tumor necrosis factor (tnf) blockers, coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive and 4 more indications. First approved in 2024.
Drug data last refreshed 19h ago
(JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate…
Worked on BARICITINIB at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Baricitinib Curative Repression of HIV-1
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults